Business Areas
CDMO Services & Products
Our Contract Development and Manufacturing Organization (CDMO) services and products encompass the commercial large-scale manufacturing of generic pharmaceutical products.
We source Active Pharmaceutical Ingredients (APIs) and excipients majorly from multiple domestic suppliers to ensure a consistent supply chain. Through our comprehensive formulation capabilities, we offer a range of dosage forms, including oral solids, oral liquids, dry syrups, and dry powder injectables. Additionally, we excel in complex delivery forms such as modified and sustained-release forms, tablets in capsules, and new technologies like nanotechnology.
Our customer engagement depends on delivering quality products consistently. With a quality-first approach, we have adhered to all quality and regulatory requirements since inception and continuously strive to improve our processes.
We place great importance on maintaining our relationships with top pharmaceutical customers, building our customer base, and strengthening our product portfolio for existing customers. More than 80% of our revenue comes from customers who have been associated with us for over five years.
Domestic Branded Generics
Driven by our marketing arm, Univentis Medicare Limited, our domestic branded generics business focuses on developing, marketing, distributing, and promoting generic pharmaceutical products under our own brand names through both offline and online channels.
We have developed a diversified branded generics product portfolio, including tablets, capsules, dry syrups, dry powder injections, ointments, and liquid orals. With a diverse product range of over 600 items, we cater to a wide spectrum of therapeutic areas.
Our product portfolio spans both acute and chronic therapeutic areas. We manufacture products in key therapeutic categories, including antibiotics/antibacterials, cephalosporins, proton pump inhibitors, anticholinergics, heparin, NSAIDs, analgesics, antipyretics, anticold & antiallergics, antiemetics, antidiabetics, antispasmodics, antifibrinolytics, cardiovascular, antioxidants & vitamins, antihyperuricemics & antigouts, fluoroquinolones & macrolides, nootropics & neurotronics/neurotrophics, antiulceratives, antimalarials anxiolytics, anticonvulsants & antipsychotics, bladder & prostate disorder, antifungals, anthelmintics & antivirals anticholinergics, anti-asthmatics & bronchodilators, and erectile dysfunction.
Our extensive pan-India network of over 5,000 distributors, along with relationships with more than 150,000 retail pharmacies nationwide, ensures widespread availability and accessibility of our products. This broad reach, combined with strong brand recognition and long-term customer relationships, strengthens our position in the Indian pharmaceutical market
International Branded Generics
In the realm of international branded generics, we target emerging, semi-regulated, and regulated markets such as the United Kingdom and Canada.
Our export product portfolio includes a diverse range of generic formulations manufactured to meet global quality standards. With a strategic emphasis on expanding our presence in key international markets, we are well-positioned to offer high-quality pharmaceutical products to a broader audience, thereby contributing to improved healthcare outcomes worldwide.
We serve over 25 countries, and our focus remains on expanding country approvals, increasing product registrations and growing our customer base and sales volumes with existing customers. With a strategic emphasis on expanding our presence in key international markets, we are well-positioned to offer high-quality pharmaceutical products to a broader audience.
Sharon Bio-Medicine Limited
The acquisition of Sharon Bio-Medicine Limited in 2023 is a strategic milestone, significantly expanding our formulation and API capabilities. Sharon’s robust manufacturing portfolio covers formulations, APIs, and intermediates, allowing us to strengthen our presence in key therapeutic areas such as cardiovascular, antifungal, antidiabetic, muscle relaxants, and antipsychotic medications.
Sharon Bio-Medicine Limited (“Sharon”) is a key player in the formulation segment, offering a wide array of generic pharmaceutical products. Sharon specializes in contract manufacturing services for formulations, ensuring affordable access to essential medicines both domestically and internationally. Our state-of-the-art facility is dedicated to the manufacturing of tablets and hard gelatin capsules to meet ever-increasing demands.
Sharon’s major formulation products include paracetamol tablets, famciclovir tablets, trazodone IR and MR tablets, Celecoxib capsules, Loperamide capsules, Ezetimibe tablets, and Azithromycin tablets.
With a strong presence in the Active Pharmaceutical Ingredient (API) market, Sharon manufactures a diverse range of APIs and intermediates essential for generic formulations. Sharon’s major API and intermediate products include Eperisone Hydrochloride, Trimetazidine Hydrochloride, Miconazole Nitrate, Ketoconazole and Nifedipine. Additionally, three API products are vertically integrated into formulations: Aripiprazole, Memantine Hydrochloride, and Trazodone Hydrochloride.
Sanctuary For Research And Development (Sa-Ford) offers services in the areas of chemistry (physico-chemical characterization, 5-batch analysis and analytical method development). Sa-Ford is a contract research facility. The facility has a maximum housing capacity of approximately 8,000 animals which comprises rats, rabbits, guinea pigs, mice, birds and fish. The facility has accreditation from AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) International. The facility is registered for research for commercial purposes and in-house breeding of small animals with the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) of India. It has also constituted the Institutional Bio-safety Committee (IBSC) which includes a nominee from the GoI’s Department of Biotechnology which is mandatory for organisations which carry out or are engaged in research activities involving genetic manipulation of genetic materials, microorganisms, plants or animals.
Through strategic integration efforts, we aim to leverage Sharon’s strengths to achieve backward integration in API manufacturing, expand our service offerings with toxicology capabilities, obtain additional accreditations for enhanced market access, and broaden our international footprint. This strategy further solidifies our position as a global leader in the pharmaceutical industry.